Sutro Biopharma

sutrobio.com

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of precisely designed cancer therapeutics. Utilizing its proprietary cell-free Xpress CF® technology, Sutro aims to improve patient outcomes through innovative antibody-drug conjugates (ADCs). The company is actively engaged in clinical trials, including the REFRαME trial for ovarian cancer, and has demonstrated a 32% objective response rate in evaluable patients. Sutro's commitment to transforming oncology positions it as a key player in the biopharmaceutical industry, with a focus on delivering next-generation therapeutics to patients.